


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :	A1	(11) International Publication Number: WO 98/49166
C07D 487/04, A61K 31/505, 31/415, C07D 231/40, 401/06		(43) International Publication Date: 5 November 1998 (05.11.98)
(21) International Application Number: PCT/EP98/02257		(74) Agents: HAYLES, James, Richard et al.; Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).
(22) International Filing Date: 10 April 1998 (10.04.98)		
(30) Priority Data:		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
9708406.5 25 April 1997 (25.04.97) GB		
9715380.3 22 July 1997 (22.07.97) GB		
9722954.6 30 October 1997 (30.10.97) GB		
(71) Applicant (for GB only): PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).		
(71) Applicant (for all designated States except GB US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).		
(72) Inventors; and		Published
(75) Inventors/Applicants (for US only): BUNNAGE, Mark, Edward [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). MATHIAS, John, Paul [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). STREET, Stephen, Derek, Albert [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). WOOD, Anthony [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION



(IA)



(IB)

(57) Abstract

Compounds of formulae (IA) and (IB) or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein R¹ is C₁ to C₃ alkyl substituted with C₃ to C₆ cycloalkyl, CONR⁵R⁶ or a N-linked heterocyclic group; (CH₂)_nHet or (CH₂)_nAr; R² is C₁ to C₆ alkyl; R³ is C₁ to C₆ alkyl optionally substituted with C₁ to C₄ alkoxy; R⁴ is SO₂NR⁷R⁸; R⁵ and R⁶ are each independently selected from H and C₁ to C₄ alkyl optionally substituted with C₁ to C₄ alkoxy, or, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic group; R⁷ and R⁸, together with the nitrogen atom to which they are attached, form a 4-R¹⁰-piperazinyl group; R¹⁰ is H or C₁ to C₄ alkyl optionally substituted with OH, C₁ to C₄ alkoxy or CONH₂; Het is an optionally substituted C-linked 5- or 6-membered heterocyclic group; Ar is optionally substituted phenyl; and n is 0 or 1; are potent and selective cGMP PDE5 inhibitors useful in the treatment of, *inter alia*, male erectile dysfunction and female sexual dysfunction.

EXPRESS MAIL NO. EU 271824876US